Faruqi & Faruqi, LLP Obtains Significant Victory On Behalf Of Investors Against ACADIA Pharmaceuticals Inc.

On September 19, 2016, United States District Judge Barry Ted Moskowitz denied a motion to dismiss filed by ACADIA Pharmaceuticals Inc. (“ACADIA”), former Chief Executive Officer (“CEO”) Uli Hacksell, current President and CEO Stephen R. Davis, and former Chief Medical Officer and Executive Vice President, Development Roger G. Mills (together “Defendants”).  The Court sustained claims alleging that the Defendants violated the federal securities laws by making materially false and misleading statements regarding the timing and status of ACADIA’s New Drug Application for its lead product candidate, Nuplazid (pimavanserin). 

If you purchased ACADIA common stock and/or call options between November 10, 2014 and March 11, 2015, inclusive, and would like to discuss your legal rights, call Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or send an e-mail to rgonnello@faruqilaw.com.